Related trials
TAxi (diabetics), 3000 - sirolimus eluting stent vs paclitaxel eluting stent
RESOLUTE All comers, 2010 - zotarolimus eluting stent vs everolimus eluting stent
SPIRIT IV, 2010 - everolimus eluting stent vs paclitaxel eluting stent
GISSOC II, 2010 - sirolimus eluting stent vs bare-metal stent
ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent vs sirolimus eluting stent
STICH (ventricular reconstruction), 2009 - CABG+surgical ventricular reconstruction vs CABG
ZEST (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent
ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol eluting stent vs sirolimus eluting stent
COMPARE, 2009 - everolimus eluting stent vs paclitaxel eluting stent
ISAR TEST 3 (BP), 2009 - sirolimus biodegradable polymer vs sirolimus eluting stent
SYNTAX, 2009 - paclitaxel eluting stent vs CABG
BARI 2D, 2009 - CABG or PCI vs medical treatment
ZEST AMI (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent
ISAR-TEST-4 (biodegradable polymer), 2009 - sirolimus biodegradable polymer vs sirolimus eluting stent
ISAR-LEFT-MAIN, 2009 - sirolimus eluting stent vs paclitaxel eluting stent
ZEST (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent
Thiele, 2009 - sirolimus ES vs MIDCAB
ENDEAVOR IV, 2009 - zotarolimus eluting stent vs paclitaxel eluting stent
ZEST AMI (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent
ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol eluting stent vs zotarolimus eluting stent
Costar II, 2008 - CoStar stent vs paclitaxel eluting stent
Boudriot, 2008 - DES vs CABG
COSTAR II diabetic (sub group), 2008 - CoStar stent vs paclitaxel eluting stent
SORT OUT II, 2008 - sirolimus eluting stent vs paclitaxel eluting stent
CARDia (PCI), 2008 - stent vs CABG
See also:
All coronary artery disease clinical trials
All stable angina clinical trials
All clinical trials of myocardial revascularization
All clinical trials of CABG or PCI
|
|
Treatments
Studied treatment |
prompt revascularization with intensive medical therapy
|
Control treatment |
intensive
medical therapy alone
|
Concomittant treatment |
with either insulin-sensitization or insulin-provision
therapy (factorial design) |
Remarks |
factorial design with 2nd comparison: insulin-sensitization or insulin-provision
therapy |
Patients
Patients |
patients with type 2 diabetes and heart disease |
Baseline characteristics |
Age (yr) |
62.4 y |
Female (%) |
29.6% |
|
Method and design
Randomized effectives |
1176 / 1192 (studied vs. control) |
Design |
Parallel groups |
Blinding |
open |
Follow-up duration |
5.3 y |
Number of centre |
49 |
Geographic area |
US, Canada, Brazil, Mexico, Czech Republic, Austria |
Primary endpoint |
death |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
5-year death
155 / 1176
161 / 1192
0,98 [0,79;1,20]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
5-year death
|
155 / 1176 (13,2%) |
161 / 1192 (13,5%) |
0,98 |
[0,79;1,20] |
end of trial |
|
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
0:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
5-year death |
13,18% |
13,51% |
-3,3‰
|
Meta-analysis of all similar trials:
myocardial revascularization in coronary artery disease for all type of patient
myocardial revascularization in coronary artery disease for diabetic patients
myocardial revascularization in stable angina for diabetic patients
myocardial revascularization in stable angina for all type of patient
Reference(s)
-
.
Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial..
Am Heart J 2008;156:528-536, 536.e1-5
Pubmed
|
Hubmed
| Fulltext
-
.
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease..
N Engl J Med 2009;:
Pubmed
|
Hubmed
| Fulltext
-
Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RL.
The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease. Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction..
Circulation 2009;:
Pubmed
|
Hubmed
| Fulltext
-
Dagenais GR, Lu J, Faxon DP, Kent K, Lago RM, Lezama C, Hueb W, Weiss M, Slater J, Frye RL.
Effects of Optimal Medical Treatment With or Without Coronary Revascularization on Angina and Subsequent Revascularizations in Patients With Type 2 Diabetes Mellitus and Stable Ischemic Heart Disease..
Circulation 2011;123:1492-1500
- 10.1161/CIRCULATIONAHA.110.978247
Pubmed
|
Hubmed
| Fulltext
|